1006390-32-4 Usage
Description
2-[4-(Aminomethyl)phenyl]-2-methylpropanenitrile is an organic compound that serves as an important intermediate in the synthesis of various pharmaceuticals and chemical compounds. It is characterized by its unique molecular structure, which features a nitrile group and an aminomethyl group attached to a phenyl ring.
Uses
Used in Pharmaceutical Industry:
2-[4-(Aminomethyl)phenyl]-2-methylpropanenitrile is used as a key intermediate in the synthesis of benzimidazole derivatives, which are known as vanilloid receptor antagonists. These derivatives have potential applications in the treatment of various conditions, such as pain, inflammation, and urinary incontinence, due to their ability to modulate the activity of vanilloid receptors.
Used in Chemical Synthesis:
In addition to its pharmaceutical applications, 2-[4-(Aminomethyl)phenyl]-2-methylpropanenitrile can also be utilized in the synthesis of other chemical compounds, such as dyes, pigments, and polymers. Its versatile molecular structure allows for further functionalization and modification, making it a valuable building block in the development of new materials and products.
Check Digit Verification of cas no
The CAS Registry Mumber 1006390-32-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,0,6,3,9 and 0 respectively; the second part has 2 digits, 3 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1006390-32:
(9*1)+(8*0)+(7*0)+(6*6)+(5*3)+(4*9)+(3*0)+(2*3)+(1*2)=104
104 % 10 = 4
So 1006390-32-4 is a valid CAS Registry Number.
1006390-32-4Relevant articles and documents
KCNT1 INHIBITORS AND METHODS OF USE
-
Page/Page column 71-72, (2022/02/06)
The present invention is directed to, in part, compounds and compositions useful for preventing and/or treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene (e.g., KCNT1). Methods of treating a neurological disease or disorder, a disease or condition relating to excessive neuronal excitability, and/or a gain-of-function mutation in a gene such as KCNT1 are also provided herein.
